Shire has entered into an agreement with Shionogi to co-develop and co-commercialize Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one-time fee and share costs in exchange for rights to jointly develop and commercialize the products for the Japanese market. Specific terms were not disclosed. “Providing support for ADHD patients, their families and the medical community who treat these patients is at the heart of our approach at Shire, and this a...